Volume Alert - NBR 16.76 Nabors Industries $NBR Hit a high

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - NBR 16.76 Nabors Industries $NBR Hit a high today of 16.90 Closing the day 10:30 at 16.76 +0.14 +0.84% With a day low of 16.54 and a total volume of 1,357,261.

NBR Recent Posts: http://investorshangout.com/Nabors-Industries-NBR-51960/

NBR Nabors Industries Recent Headline News

After Yesterday's Decline of 3.60%, Nabors Industries Offers Investors Better Value
Comtex SmarTrend(R) - Thu Nov 13, 4:24PM CST
Nabors Industries (NYSE:NBR) traded in a range yesterday that spanned from a low of $16.03 to a high of $17.09. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $17.01 on volume of 13.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBR: 16.27 (-0.35)

Nabors Industries Set to Possibly Rebound After Yesterday's Selloff of 3.60%
Comtex SmarTrend(R) - Thu Nov 13, 4:23PM CST
Nabors Industries (NYSE:NBR) traded in a range yesterday that spanned from a low of $16.03 to a high of $17.09. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $17.01 on volume of 13.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBR: 16.27 (-0.35)

Nabors Industries (NBR) Stock Falls as Oil Prices Hit Four-Year Low
at The Street - Thu Nov 13, 2:43PM CST
Shares of Nabors Industries (NBR) declined on Thursday after crude oil prices hit a four-year low.
NBR: 16.27 (-0.35)

Helmerich & Payne (HP) Q4 Earnings Miss, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 9:35AM CST
Contract drilling services provider Helmerich & Payne Inc. (HP) reported weaker-than-expected earnings but beat revenue estimates.
RIG: 26.00 (-0.29), NBR: 16.27 (-0.35), HP: 78.44 (-1.35), PTEN: 20.94 (-0.14)

Nabors Industries Has Returned 34.7% Since SmarTrend Recommendation (NBR)
Comtex SmarTrend(R) - Wed Nov 12, 4:52PM CST
SmarTrend identified a Downtrend for Nabors Industries (NYSE:NBR) on August 1st, 2014 at $26.39. In approximately 3 months, Nabors Industries has returned 34.67% as of today's recent price of $17.24.
NBR: 16.27 (-0.35)

Will Helmerich & Payne (HP) Miss on Earnings this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:30AM CST
Helmerich & Payne, Inc. (HP) is set to release fourth-quarter fiscal 2014 financial results before the opening bell on Thursday, Nov 13.
DO: 35.53 (+0.25), SDT: 4.10 (+0.08), NBR: 16.27 (-0.35), HP: 78.43 (-1.36)

Nabors Industries upwardly revises Q3 earnings from continuing ops
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 2:46PM CST

NBR: 16.27 (-0.35)

Nabors beats 3Q profit forecasts
Automated Insights - Tue Nov 11, 11:45AM CST
HAMILTON HM08, Bermuda (AP) _ Nabors Industries Ltd. (NBR) on Tuesday reported third-quarter net income of $106 million.
NBR: 16.27 (-0.35)

Nabors Announces Revised Third Quarter 2014 Results; GAAP Earnings per Share of $0.34
CNW Group - Mon Nov 10, 5:54PM CST
Nabors Industries Ltd. (NYSE:NBR) today reported revised third-quarter 2014 diluted earnings per share from continuing operations of $0.34, versus the $0.19 previously announced in our earnings press release for the third quarter of 2014 that was issued on October 21, 2014. The revision is due to a change in the non-cash income tax provision for the third quarter. Upon review, it was determined that the previously reported $63.3 million non-cash tax charge related to the restructuring of the Company's completion and production entities in preparation for the pending transaction with C&J Energy Services should be reduced by approximately $45.0 million to $18.3 million.
CJES: 19.81 (-0.07), NBR: 16.27 (-0.35)

Nabors Industries (NBR) Breaks Through Support at $16.34
Comtex SmarTrend(R) - Thu Nov 06, 9:30AM CST
Shares of Nabors Industries (NYSE:NBR) opened today below their pivot of $16.76 and have already reached the first level of support at $16.34. Analysts will be watching for a cross of the next downside pivot targets of $16.02 and $15.28.
NBR: 16.27 (-0.35)

Oil and Gas Firms Turn to Technology to Weather Low Energy Prices
at The Street - Wed Nov 05, 12:46PM CST
Lower energy prices are delaying capital spending and highlighting the need for advanced technology. Is that the new golden goose for E&P companies?
RDS.A: 69.14 (+0.73), HES: 82.47 (+1.37), TOT: 57.31 (+0.33), NBR: 16.27 (-0.35), WFT: 16.20 (-0.13), XOM: 94.78 (+0.12), DD: 70.71 (+0.16), COP: 71.04 (+0.69), BP: 40.93 (+0.26), GLRI: 4.52 (-0.01), SLB: 95.25 (+0.40)

Shares of NBR Down 35.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Nov 05, 10:59AM CST
SmarTrend identified a Downtrend for Nabors Industries (NYSE:NBR) on August 1st, 2014 at $26.39. In approximately 3 months, Nabors Industries has returned 35.92% as of today's recent price of $16.91.
NBR: 16.27 (-0.35)

Oil & Gas Stocks: Does This Correction Have Logic To It?
Richard Zeits - at Seeking Alpha - Wed Nov 05, 6:00AM CST

NBL: 55.30 (+1.31), WLL: 55.50 (+0.61), CLR: 53.49 (+0.89), NBR: 16.28 (-0.34), HAL: 54.56 (+0.77), XOM: 94.78 (+0.12), SN: 16.34 (-0.02), SDRL: 20.70 (+0.05), LPI: 17.32 (+0.26), AREX: 12.60 (+1.14), PBR: 9.93 (-0.27), RDS.A: 69.14 (+0.73), RIG: 26.00 (-0.29), CVX: 115.97 (-0.48), OAS: 25.93 (+0.21), STO: 22.02 (+0.45), BHI: 58.87 (+0.12)

Nabors Industries (NBR) Stock Slumps Today as Oil Prices Fall
at The Street - Tue Nov 04, 1:05PM CST
Shares of Nabors Industries (NBR) are falling after West Texas Intermediate crude slid to as low as $75.84.
NBR: 16.29 (-0.33)

Oil and Gas Drilling Equities Technical Analysis - Precision Drilling, Paragon Offshore, Helmerich and Payne, Vantage Drilling, and Nabors Industries
PR Newswire - Mon Nov 03, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Precision Drilling Corporation (NYSE: PDS), Paragon Offshore PLC (NYSE: PGN), Helmerich and Payne Inc. (NYSE: HP), Vantage Drilling Company (NYSE MKT: VTG), and Nabors Industries Ltd (NYSE: NBR). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 31, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,390.52, up 1.13% and the NASDAQ Composite closed at 4,630.74, up 1.41%. The S&P 500 finished the session 1.17% higher at 2,018.05. During the trading session, all the ten sectors finished on a higher note. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Energy Sector Index ended the day at 641.32, up 2.04%, with the index advancing 1.89% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
VTG: 0.87 (-0.02), NBR: 16.28 (-0.34), PDS: 7.83 (+0.11), HP: 78.43 (-1.36), PGN: 4.76 (-0.07)

Oil Price Collapse Cannot Be Good For Drillers But May Create Value Plays In Producers
Michael Blair - Seeking Alpha - Thu Oct 30, 3:06PM CDT
Oil prices continue to plunge taking a lot of solid oil & gas companies down with them. The Western Canadian Sedimentary Basin is full of opportunity today. But how low can prices go? The answer is they can go a lot lower. That is the bad news....
BXE: 4.61 (+0.06), UNT: 45.89 (+0.37), PWE: 4.13 (+0.07), NBR: 16.28 (-0.34), PKD: 3.98 (-0.04), PGH: 3.75 (unch), HP: 78.43 (-1.36), PTEN: 20.96 (-0.12)

Nabors Industries (NBR) Approaches New Downside Target of $17.23
Comtex SmarTrend(R) - Thu Oct 30, 12:59PM CDT
Shares of Nabors Industries (NYSE:NBR) have bearishly opened below the pivot of $17.94 today and have reached the first support level of $17.58. Investors may be interested in a cross of the next downside pivot targets of $17.23 and $16.52.
NBR: 16.29 (-0.33)

C&J Energy Services Announces Third Quarter 2014 Results
PR Newswire - Wed Oct 29, 3:05PM CDT
C&J Energy Services, Inc. (NYSE: CJES) today reported net income of $23.8 million, or $0.42 per diluted share, on revenue of $440.0 million for the third quarter of 2014, and Adjusted Net Income(1) of $26.5 million, or $0.47 per diluted share(1), after excluding a $2.7 million after-tax ($0.05 per diluted share) charge related to transaction costs associated primarily with the proposed combination (the "Pending Transaction" of C&J with the completion and production services business of Nabors Industries Ltd. ("Nabors" . These results compare with net income of $11.1 million, or $0.20 per diluted share, on revenue of $367.9 million for the second quarter of 2014 and Adjusted Net Income(1) of $15.7 million, or $0.28 per diluted share(1), after excluding a $4.6 million after-tax ($0.08 per diluted share) charge related to the aforementioned transaction costs. For the third quarter of 2013, the Company recorded net income of $13.1 million, or $0.24 per diluted share, on revenue of $261.9 million. Adjusted EBITDA(1) for the third quarter of 2014 was $75.2 million, compared to $53.0 million for the second quarter of 2014 and $42.9 million for the third quarter of 2013.
CJES: 19.82 (-0.06), NBR: 16.29 (-0.33)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 446

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 333

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 38

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 90

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 104

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

SOCi's AI Marketing: Leading G2's Summer 2026 Rankings

Updated Category News Views 12

AI's Rising Star in Enterprise Marketing Here's a tidbit worth chewing over your morning coffee: SOCi Inc., a name that's been buzzing in the enterprise circles, has nailed top spots in G2's Summer 2026 Report. We're talking about leading the charge in AI marketing and localized visibility, territories tough to crack unless you've got serious chops. In a world where...

Continue Reading
AI and the Future of Staffing: A Market Growth Story

Updated Category News Views 344

AI and the Future of Staffing: A Growth Story The staffing services market is on the verge of a major transformation, thanks in large part to advancements in Artificial Intelligence (AI). This evolution is projected to add an astounding USD 236.6 billion to the global staffing services market between 2024 and 2028. During this time, the market is expected to experience a...

Continue Reading
Optical Innovations Unite: OCC and Lightera's New Partnership

Updated Category News Views 317

Strategic Collaboration Between OCC and Lightera Optical Cable Corporation (NASDAQ: OCC) and Lightera, LLC are entering a significant partnership aimed at enhancing their product offerings primarily in the data center and enterprise sectors. This collaboration builds upon their long-term relationship, combining their strengths to create innovative optical connectivity...

Continue Reading
INFINOX Welcomes Artem Gonov as New Chief Technology Officer

Updated Category News Views 148

INFINOX Appoints Artem Gonov as Chief Technology Officer INFINOX, a globally recognized brokerage, has recently appointed Artem Gonov as its new Chief Technology Officer (CTO). This strategic move underlines the company's commitment to enhancing its technology landscape and providing exceptional platforms for its clients. Artem Gonov's Background and Expertise Mr. Gonov...

Continue Reading
George Medicines’ GMRx2 Sets New Standard for Hypertension Care

Updated Category News Views 126

George Medicines Introduces GMRx2 for Hypertension Management Recent findings published in The Lancet highlighted the promising results of a Phase III trial for GMRx2, a novel triple combination pill aimed at managing hypertension. Developed by George Medicines, this medication is making waves in the field of cardiovascular care as it demonstrates significant advancements...

Continue Reading